- Home
- ESPR vs GDEV Comparison
ESPR vs GDEV Comparison
Compare ESPR & GDEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- GDEV
- Stock Information
- Founded
- ESPR 2008
- GDEV 2009
- Country
- ESPR United States
- GDEV Cyprus
- Employees
- ESPR N/A
- GDEV N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- GDEV EDP Services
- Sector
- ESPR Health Care
- GDEV Technology
- Exchange
- ESPR Nasdaq
- GDEV Nasdaq
- Market Cap
- ESPR 305.0M
- GDEV N/A
- IPO Year
- ESPR 2013
- GDEV N/A
- Fundamental
- Price
- ESPR $0.89
- GDEV $15.45
- Analyst Decision
- ESPR Buy
- GDEV Buy
- Analyst Count
- ESPR 7
- GDEV 2
- Target Price
- ESPR $5.93
- GDEV $70.00
- AVG Volume (30 Days)
- ESPR 5.7M
- GDEV 37.4K
- Earning Date
- ESPR 05-06-2025
- GDEV 05-27-2025
- Dividend Yield
- ESPR N/A
- GDEV N/A
- EPS Growth
- ESPR N/A
- GDEV N/A
- EPS
- ESPR N/A
- GDEV 1.38
- Revenue
- ESPR $259,574,000.00
- GDEV $420,933,000.00
- Revenue This Year
- ESPR $5.70
- GDEV $4.73
- Revenue Next Year
- ESPR N/A
- GDEV $16.15
- P/E Ratio
- ESPR N/A
- GDEV $11.17
- Revenue Growth
- ESPR 12.99
- GDEV N/A
- 52 Week Low
- ESPR $0.82
- GDEV $8.60
- 52 Week High
- ESPR $3.94
- GDEV $42.76
- Technical
- Relative Strength Index (RSI)
- ESPR 36.95
- GDEV 62.08
- Support Level
- ESPR $0.93
- GDEV $10.25
- Resistance Level
- ESPR $1.11
- GDEV $18.33
- Average True Range (ATR)
- ESPR 0.10
- GDEV 1.43
- MACD
- ESPR 0.02
- GDEV 0.79
- Stochastic Oscillator
- ESPR 25.10
- GDEV 64.36
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.